Advertisement

Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

Genmab A/S. (6/2/15). "Press Release: Genmab to Present at the Goldman Sachs 36th Annual Global Healthcare Conference". Copenhagen.

Organisations Organisation Genmab A/S (CSE: GEN, Nasdaq: GMAB)
  Group Genmab (Group)
  Organisation 2 Goldman Sachs (Group)
Products Product Goldman Sachs Annual Global Healthcare Conference 2015 Rancho Palos Verdes, CA
  Product 2 DuoBody technology platform (bispecific antibodies)
Index term Index term Genmab–Goldman Sachs: investor conference, 201506 supply service Genmab presents at 36th Annual Global Healthcare Conference
Persons Person van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
  Person 2 Curtis Gravesen, Rachel (Consilium Strategic Communications 201909– Senior Strategic Advisor before Genmab + Novo)
     


Genmab A/S (OMX: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, California at 4:00PM PDT on June 9, 2015 / 1:00AM CEST on June 10, 2015. A webcast of the presentation will be available on Genmab's website at http://ir.genmab.com/events.cfm.


About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin's lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates. Partnering of selected innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com


This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis Pharma AG.

Media Release no. 04
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

   
Record changed: 2016-01-10

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Genmab (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81




» top